Skip to main content

Annual Dilbert (headlines) post


Szczekociny festival poster
Scott Adams, the cartoonist who created Dilbert, has said that there are only nine news stories, constantly re-written. 

Every year at about this time I like to check the newspaper with his list in mind, to see if he is right. I'll start with his wording unmodified by examples. 

1. EXTREME WEATHER BATTERS SOMEPLACE
2. IDIOTS KILL INNOCENT PEOPLE
3. POLITICIAN DOES SOMETHING ILLEGAL
4. PRIMATE ATTEMPTS INAPPROPRIATE SEX
5. EXPERT WARNS OF FINANCIAL CALAMITY
6. BIG COMPANY BUYS ANOTHER BIG COMPANY
7. FAMOUS PERSON DOES SOMETHING INTERESTING
8. A SCIENTIFIC DISCOVERY MIGHT BE USEFUL IN TEN YEARS
9. GOVERNMENT FAILS TO ACHIEVE A GOAL 

I surveyed the news on one day (a few days back as it happens). Just by convenience, these headlines are all from January 21st. Well, actually, I cheated a little with one of them, but I'll let you dear reader do the work of figuring out which one that is. Without further ado....

1. An extraordinary South African drought.
2. Let's not include anything fancy, like terrorism. Just old-fashioned dumbass murder.
3. I take the word "politician" here to include Vladimir Putin.
4. This time around let's celebrate the successful reproduction of a spider monkey pair.
5. Experts have started worrying whether oil companies are Too Big to Fail.
6. Foxconn offers $5.3 billion in US money for that other big company, Sharp.
7. Real-world heroics from Jamie Foxx.
8. Heck, in those ten years we might want to travel to yet another planet.
9. The switch to Flint River water? Brilliant idea, yes?

Dilbert's right. Except for those proud parental monkeys, we're in a loop. 

Comments

Popular posts from this blog

A Story About Coleridge

This is a quote from a memoir by Dorothy Wordsworth, reflecting on a trip she took with two famous poets, her brother, William Wordsworth, and their similarly gifted companion, Samuel Taylor Coleridge.



We sat upon a bench, placed for the sake of one of these views, whence we looked down upon the waterfall, and over the open country ... A lady and gentleman, more expeditious tourists than ourselves, came to the spot; they left us at the seat, and we found them again at another station above the Falls. Coleridge, who is always good-natured enough to enter into conversation with anybody whom he meets in his way, began to talk with the gentleman, who observed that it was a majestic waterfall. Coleridge was delighted with the accuracy of the epithet, particularly as he had been settling in his own mind the precise meaning of the words grand, majestic, sublime, etc., and had discussed the subject with William at some length the day before. “Yes, sir,” says Coleridge, “it is a majestic wate…

Hume's Cutlery

David Hume is renowned for two pieces of cutlery, the guillotine and the fork.

Hume's guillotine is the sharp cut he makes between "is" statements and "ought" statements, to make the point that the former never ground the latter.

His "fork" is the division between what later came to be called "analytic" and "synthetic" statements, with the ominous observation that any books containing statements that cannot be assigned to one or the other prong should be burnt.

Actually, I should acknowledge that there is some dispute as to how well or poorly the dichotomy Hume outlines really maps onto the analytic/synthetic dichotomy. Some writers maintain that Hume meant something quite different and has been hijacked. Personally, I've never seen the alleged difference however hard they've worked to point it out to me.

The guillotine makes for a more dramatic graphic than a mere fork, hence the bit of clip art above.

I'm curious whe…

Cancer Breakthrough

Hopeful news in recent days about an old and dear desideratum: a cure for cancer. Or at least for a cancer, and a nasty one at that.

The news comes about because investors in GlaxoSmithKline are greedy for profits, and has already inspired a bit of deregulation to boot. 

The FDA has paved the road for a speedy review of a new BCMA drug for multiple myeloma, essentially cancer of the bone marrow. This means that the US govt has removed some of the hurdles that would otherwise (by decision of the same govt) face a company trying to proceed with these trials expeditiously. 

This has been done because the Phase I clinical trial results have been very promising. The report I've seen indicates that details of these results will be shared with the world on Dec. 11 at the annual meeting of the American Society of Hematology. 

The European Medicines Agency has also given priority treatment to the drug in question. 

GSK's website identifies the drug at issue as "GSK2857916," althou…